Alpidem in the treatment of panic disorder

Franklin R. Schneier, Jose L. Carrasco, Eric Hollander, Raphael Campeas, Brian Fallon, Jihad B. Saoud, John Feerick, Michael R. Liebowitz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Alpidem, an imidazopyridine that acts at the y-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8–week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.

Original languageEnglish (US)
Pages (from-to)150-153
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume13
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Panic Disorder
Aminobutyrates
Therapeutics
Agoraphobia
Anti-Anxiety Agents
GABA-A Receptors
Benzodiazepines
Anxiety
alpidem
Clinical Trials

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Schneier, F. R., Carrasco, J. L., Hollander, E., Campeas, R., Fallon, B., Saoud, J. B., ... Liebowitz, M. R. (1993). Alpidem in the treatment of panic disorder. Journal of Clinical Psychopharmacology, 13(2), 150-153.

Alpidem in the treatment of panic disorder. / Schneier, Franklin R.; Carrasco, Jose L.; Hollander, Eric; Campeas, Raphael; Fallon, Brian; Saoud, Jihad B.; Feerick, John; Liebowitz, Michael R.

In: Journal of Clinical Psychopharmacology, Vol. 13, No. 2, 1993, p. 150-153.

Research output: Contribution to journalArticle

Schneier, FR, Carrasco, JL, Hollander, E, Campeas, R, Fallon, B, Saoud, JB, Feerick, J & Liebowitz, MR 1993, 'Alpidem in the treatment of panic disorder', Journal of Clinical Psychopharmacology, vol. 13, no. 2, pp. 150-153.
Schneier FR, Carrasco JL, Hollander E, Campeas R, Fallon B, Saoud JB et al. Alpidem in the treatment of panic disorder. Journal of Clinical Psychopharmacology. 1993;13(2):150-153.
Schneier, Franklin R. ; Carrasco, Jose L. ; Hollander, Eric ; Campeas, Raphael ; Fallon, Brian ; Saoud, Jihad B. ; Feerick, John ; Liebowitz, Michael R. / Alpidem in the treatment of panic disorder. In: Journal of Clinical Psychopharmacology. 1993 ; Vol. 13, No. 2. pp. 150-153.
@article{5d6dbc5363bd44d8906be0156c840c4f,
title = "Alpidem in the treatment of panic disorder",
abstract = "Alpidem, an imidazopyridine that acts at the y-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8–week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.",
author = "Schneier, {Franklin R.} and Carrasco, {Jose L.} and Eric Hollander and Raphael Campeas and Brian Fallon and Saoud, {Jihad B.} and John Feerick and Liebowitz, {Michael R.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "150--153",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Alpidem in the treatment of panic disorder

AU - Schneier, Franklin R.

AU - Carrasco, Jose L.

AU - Hollander, Eric

AU - Campeas, Raphael

AU - Fallon, Brian

AU - Saoud, Jihad B.

AU - Feerick, John

AU - Liebowitz, Michael R.

PY - 1993

Y1 - 1993

N2 - Alpidem, an imidazopyridine that acts at the y-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8–week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.

AB - Alpidem, an imidazopyridine that acts at the y-aminobutyric acid/benzodiazepine receptor complex, has been reported to be an effective anxiolytic with a more favorable side effect profile than benzodiazepines. The effect of alpidem was investigated in an 8–week, open, clinical trial in 13 patients with panic disorder, with or without agoraphobia. Three patients were responders (much improved or very much improved), five patients were nonresponders, and five patients dropped out after less than 6 weeks of treatment. Significant improvement was seen in the sample as a whole for spontaneous panic attacks, phobic avoidance, and anticipatory anxiety. Most improvement occurred during the first 4 weeks of treatment, and responders had milder panic disorder at baseline. Adverse effects were generally mild. After 8 weeks of treatment, taper of medication over 2 weeks occurred without significant worsening of panic disorder symptoms. The efficacy of alpidem in the treatment of panic disorder remains uncertain and requires assessment in a controlled trial.

UR - http://www.scopus.com/inward/record.url?scp=0027450754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027450754&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 150

EP - 153

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -